

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1. (Currently Amended) A method of enhancing expression of a desired protein at mucosal effector sites of a mammal, ~~said the~~ method comprising placing a nucleotide sequence encoding the protein to be expressed under ~~the~~ control of a promoter having the nucleotide sequence of SEQ ID NO: 2 in a recombinant gut-colonizing microorganism, administering the microorganism to the mammal, and causing expression of the desired protein in mucosal cells ~~in a construct, which is administered to mucosal cells.~~

2-22. Cancelled.

23. (Currently Amended) The method of claim 1, wherein the desired protein induces a protective immune response against a pathogen in the a mammal ~~to which the protein is administered.~~

24. (Cancelled).

25. (Currently Amended) The method of claim 23 24, wherein the desired protein is heterologous to the recombinant gut-colonising microorganism.

26. (Currently Amended) The method of claim 23 24, wherein the recombinant gut-colonising microorganism is a *Salmonella* spp.

27. (Previously Presented) The method of claim 26, wherein the *Salmonella* spp. is *Salmonella typhimurium* or *Salmonella typhi*.

28. (Currently Amended) The method of claim 1 24, wherein the recombinant gut-colonising microorganism is attenuated.

29. (Currently Amended) The method of claim 23, wherein the pathogen protein is able to induce a protective immune response against *Yersinia pestis*.

30. (Currently Amended) The method of claim 29, wherein the desired protein comprises the F1-antigen of *Yersinia pestis*.

31. (Currently Amended) The method of claim 23 24, wherein the recombinant gut-colonising microorganism is administered as a composition which further comprises a pharmaceutically acceptable carrier or diluent.

32. (Previously Presented) The method of claim 31, wherein the composition is adapted for oral administration.